[Clinical study of ucb 3983 in pediatric (author's transl)].
D000336:Aerosols; D000476:Alkanesulfonates / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D001996:Bronchopneumonia / Q000188:drug therapy; D002675:Child, Preschool; D003348:Cortisone / Q000627:therapeutic use; D003371:Cough; D003550:Cystic Fibrosis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005100:Expectorants / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009157:Myasthenia Gravis / Q000188:drug therapy; D012140:Respiratory Tract Diseases / Q000188:drug therapy*; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*
D000336:Aerosols; D000476:Alkanesulfonates; D000900:Anti-Bacterial Agents; D001993:Bronchodilator Agents; D005100:Expectorants; D013438:Sulfhydryl Compounds; D003348:Cortisone
Etude clinique de l'ucb 3983 en pédiatrie.